Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H22N2O4 |
| Molecular Weight | 354.3997 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(=O)OCC(=O)N(C)C)C1=CC=C2OC3=NC(C)=CC=C3CC2=C1
InChI
InChIKey=ZAKRMJAETCUYKK-UHFFFAOYSA-N
InChI=1S/C20H22N2O4/c1-12-5-6-15-10-16-9-14(7-8-17(16)26-19(15)21-12)13(2)20(24)25-11-18(23)22(3)4/h5-9,13H,10-11H2,1-4H3
| Molecular Formula | C20H22N2O4 |
| Molecular Weight | 354.3997 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/1814850Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/7996395
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1814850
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/7996395
N,N-Dimethylcarbamoylmethyl alpha,2-dimethyl-5H-[1]- benzopyrano[2,3-b]pyridine-7-acetate (Y-23023/ Tilnoprofen arbamel) is a prodrug developed as a new non-steroidal anti-inflammatory drug (NSAID), by Yoshitomi and Japan Tobacco for treatment pain in Rheumatoid arthritis, but was discontinued. Y-23023 is rapidly hydrolysed to an active metabolite, alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetic acid (TILNOPROFENIC ACID), cyclo-oxygenase inhibitor.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1814850 |
|||
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8537074 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Mechanism of analgesic action of Y-23023, a new non-steroidal anti-inflammatory drug]. | 1995-10 |
|
| Inhibition by cyclo-oxygenase inhibitors of interleukin-6 production by human peripheral blood mononuclear cells. | 1991 |
|
| [Synthesis, pharmacological activity and biopharmaceutical characteristics of alpha,2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetates]. | 1989-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://adisinsight.springer.com/drugs/800003086
Unknown
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/1814850
Y-9223 (TILNOPROFENIC ACID), a novel cyclo-oxygenase inhibitor, inhibited the increases in the IL-6 level in the culture medium of both mitogen-stimulated adherent cells and non-adherent cells fractionated from mononuclear cells of human peripheral blood. Northern blotting showed that the mitogen-induced increase in the expression of IL-6 mRNA was inhibited by Y-9223, indicating that this agent inhibits IL-6 biosynthesis.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:20:24 GMT 2025
by
admin
on
Wed Apr 02 08:20:24 GMT 2025
|
| Record UNII |
HY45T0EF6G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB11055MIG
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL1968603
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
7397
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
C063558
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
164072
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
159098-79-0
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
SUPERSEDED | |||
|
118635-52-2
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
100000082698
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
C76820
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
DTXSID4048852
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY | |||
|
HY45T0EF6G
Created by
admin on Wed Apr 02 08:20:24 GMT 2025 , Edited by admin on Wed Apr 02 08:20:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|